AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome
- Interim analysis expected around year-end 2022, informing Phase 2 start
- Trial progressing with regulatory clearances in the UK and also now in Spain
- Planned submission of U.S. Investigational New Drug application in Q1 2023
- Continues progress towards prevention of neurodegenerative diseases
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided an update on the Phase 1b/2 ABATE study of its anti-amyloid-beta (Abeta) vaccine candidate ACI-24.060 in patients with prodromal Alzheimer’s disease (AD) and individuals with Down syndrome (DS). With regulatory clearances now in both the UK and Spain, clinical sites are open and recruiting.